Accelerate Diagnostics, Inc.
Accelerate Diagnostics, Inc. (AXDX) Revenue
Annual & quarterly revenue history · segment & region breakdown
AXDX · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsAccelerate Diagnostics, Inc. trailing twelve-month (TTM) revenue is $0.01B, a decrease of 2.99% year-over-year from $0.01B in FY2024.
Revenue trend
2024 – 2005 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2024-12-31 | $0.01B | -$0.00B | -2.99% |
| 2023-12-31 | $0.01B | -$0.00B | -5.43% |
| 2022-12-31 | $0.01B | +$0.00B | +8.23% |
| 2021-12-31 | $0.01B | +$0.00B | +5.53% |
| 2020-12-31 | $0.01B | +$0.00B | +20.09% |
| 2019-12-31 | $0.01B | +$0.00B | +63.97% |
| 2018-12-31 | $0.01B | +$0.00B | +35.74% |
| 2017-12-31 | $0.00B | +$0.00B | +1597.97% |
| 2016-12-31 | $0.00B | +$0.00B | +67.35% |
| 2015-12-31 | $0.00B | +$0.00B | +20.49% |
Revenue breakdown
Segment & GeographyAbout Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Accelerate Diagnostics, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Accelerate Diagnostics, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Accelerate Diagnostics, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
AXDX revenue · 4 questionsAXDX's trailing twelve-month (TTM) revenue is $0.01B. That is a decrease of 2.99% year-over-year from $0.01B in FY2024.
▸ Source: FMP · Accelerate Diagnostics, Inc. SEC filings · GAAP · Accelerate Diagnostics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026